Quidel Co. (NASDAQ:QDEL) – Equities researchers at William Blair issued their Q1 2018 earnings per share estimates for shares of Quidel in a research report issued on Wednesday, April 4th. William Blair analyst B. Weinstein anticipates that the company will post earnings per share of $0.89 for the quarter. William Blair also issued estimates for Quidel’s Q2 2018 earnings at $0.14 EPS, Q3 2018 earnings at $0.52 EPS, Q4 2018 earnings at $0.72 EPS and FY2018 earnings at $2.27 EPS.
A number of other analysts also recently weighed in on QDEL. Canaccord Genuity increased their price target on Quidel from $55.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday. ValuEngine raised shares of Quidel from a “sell” rating to a “hold” rating in a research report on Tuesday. BidaskClub raised shares of Quidel from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, March 27th. Barclays increased their price objective on shares of Quidel from $60.00 to $63.00 and gave the stock an “overweight” rating in a research report on Monday, April 2nd. Finally, Piper Jaffray reissued a “buy” rating and set a $63.00 price objective on shares of Quidel in a research report on Wednesday. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $57.29.
Shares of Quidel stock opened at $51.22 on Friday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.58 and a quick ratio of 2.06. Quidel has a 1-year low of $22.25 and a 1-year high of $54.16. The stock has a market cap of $1,856.59, a price-to-earnings ratio of -731.71, a price-to-earnings-growth ratio of 0.91 and a beta of 0.89.
Quidel (NASDAQ:QDEL) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $0.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.70. Quidel had a negative return on equity of 3.02% and a negative net margin of 2.94%. The firm had revenue of $114.90 million during the quarter, compared to the consensus estimate of $115.06 million. During the same period last year, the business posted $0.17 EPS. The business’s revenue was up 117.6% compared to the same quarter last year.
In related news, CEO Douglas C. Bryant sold 36,000 shares of the firm’s stock in a transaction dated Thursday, March 29th. The shares were sold at an average price of $51.63, for a total value of $1,858,680.00. Following the transaction, the chief executive officer now owns 306,313 shares of the company’s stock, valued at approximately $15,814,940.19. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jack W. Schuler sold 12,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $48.50, for a total transaction of $582,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 120,000 shares of company stock worth $5,751,720 in the last three months. Insiders own 22.00% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. California Public Employees Retirement System lifted its position in Quidel by 2.9% in the 4th quarter. California Public Employees Retirement System now owns 59,799 shares of the company’s stock valued at $2,592,000 after acquiring an additional 1,696 shares in the last quarter. Tamarack Advisers LP lifted its position in Quidel by 80.0% in the 4th quarter. Tamarack Advisers LP now owns 270,000 shares of the company’s stock valued at $11,705,000 after acquiring an additional 120,000 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Quidel by 4.0% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 181,804 shares of the company’s stock valued at $7,974,000 after acquiring an additional 7,016 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Quidel by 10.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 857,195 shares of the company’s stock valued at $37,159,000 after acquiring an additional 83,894 shares in the last quarter. Finally, OppenheimerFunds Inc. lifted its position in Quidel by 206.6% in the 4th quarter. OppenheimerFunds Inc. now owns 630,052 shares of the company’s stock valued at $27,313,000 after acquiring an additional 424,580 shares in the last quarter. 93.28% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/07/brokers-issue-forecasts-for-quidel-co-s-q1-2018-earnings-qdel.html.
Quidel Company Profile
Quidel Corporation is engaged in the development, manufacturing and marketing of diagnostic testing solutions. These diagnostic testing solutions are separated into four product categories: immunoassays, molecular assays, virology and specialty products. The Company sells its products directly to end users and distributors, in each case, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail clinics, pharmacies and wellness screening centers.
Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.